Stockwatch: A Brief History Of Asset Swaps
This article was originally published in Scrip
Even with the proposed acquisition of Allergan Plc by Pfizer Inc., 2015 was not so much the year of life science M&A or even the bursting of the biotech bubble but the rise in the asset-swapping imperative. The jury is almost certainly still out for this development amongst big pharmaceutical companies so unlike the pharmaceutical mega-merger there is at least one reason why we may continue to see asset swap transactions in 2016.
Register for our free email digests: